An announcement from Day One Biopharmaceuticals ( (DAWN) ) is now available.
On February 25, 2025, Day One Biopharmaceuticals announced its financial results for the fourth quarter and full year 2024, reporting OJEMDA net product revenues of $29.0 million for Q4 and $57.2 million for the year. The company ended 2024 with $531.7 million in cash and investments, and highlighted the approval of OJEMDA as a catalyst for growth. Significant achievements included the Exclusively Pediatric designation for OJEMDA, progress in clinical trials, and increased R&D and SG&A expenses. The announcement reflects Day One’s strategic positioning for long-term growth and its commitment to advancing pediatric cancer treatments.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biopharmaceutical company focused on developing and commercializing targeted therapies for individuals of all ages with life-threatening diseases, particularly pediatric cancer. The company collaborates with clinical oncologists, families, and scientists to develop important cancer treatments, including their products tovorafenib (OJEMDA), DAY301, and a VRK1 inhibitor program.
YTD Price Performance: -4.17%
Average Trading Volume: 964,356
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.23B
See more data about DAWN stock on TipRanks’ Stock Analysis page.